Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

SPRO Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Spero Therapeutics, Inc.NASDAQ: SPRO

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 99.8% from a year ago

Net receivables stood at $44K at the end of Q1 FY2026, down 99.8% from a year earlier and down 99.8% from the prior quarter. Over 3 fiscal years it compounded at +186.1% a year.

Context

  • Net receivables amounted to 0.1% of total assets at the end of Q1 FY2026, down 31.2 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -99.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$44K-99.8% QoQ
Last fiscal yearDec 2025
$25.39M-51.6% YoY
Year agoMar 2025
$24.28M-99.8% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.8%——
1 year-51.6%——
3-year CAGR+186.1%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
25.39M USD
Year-over-year change
-51.6%
4-year CAGR
+76.1%

Net Receivables vs competitors

How SPRO compares with its peers on the latest reported figures

  • SPRO's Mar 2026 net receivables of $44K is the 6th highest of the 10 companies compared; the peer median is $233K.
  • Its year-over-year change of -99.8% is the 6th highest of 8, against a peer median of -42.9%.
  • Net receivables amounts to 0.1% of total assets for SPRO, versus a peer median of 0.2%.
SPRO Competitors Peer median
Net Receivables for SPRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEERSeer, Inc.Mar 2026$4.26M -20.5%-5.3%1.6%
CGTXCognition Therapeutics, Inc.Mar 2026$3.66M -23.5%+39.3%10.1%
IRDOpus Genetics, Inc.Mar 2026$2.72M -42.9%-13.3%4.1%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$772K +105.3%—0.6%
MCRBSeres Therapeutics, Inc.Mar 2026$233K -94.7%—0.2%
SPROSpero Therapeutics, Inc.Mar 2026$44K -99.8%+186.1%0.1%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 -100.0%-96.6%0.0%
HURATuHURA Biosciences, Inc.Mar 2026$0 -100.0%—0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 ——0.0%
ACTUActuate Therapeutics IncMar 2026$0 ——0.0%
Peer median (excluding SPRO) $233K-42.9%-9.3%0.2%

Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents112.58M109.11M76.33M52.89M40.27M
Short-term Investments33.82M0000
Net Receivables2.64M1.08M50.7M52.48M25.39M
Inventory0(4.46M)000
Other Current Assets03.38M4.18M1.91M1.63M
Total Current Assets157.87M109.11M131.21M107.28M67.29M
Property, Plant & Equipment (Net)7.56M5.49M4.16M3.11M1.48M
Goodwill00000
Intangible Assets00000
Long-term Investments0046.59M00
Tax Assets00000
Other Non-current Assets5.64M10.2M435K153K153K
Total Non-current Assets13.2M15.7M51.18M3.27M1.63M
Total Assets171.07M124.8M182.39M110.54M68.92M
Account Payables1.1M617K1.38M7.31M693K
Short-term Debt01.69M1.72M1.75M1.96M
Tax Payables00387K174K383K
Deferred Revenue1.86M10.37M27.11M22.12M258K
Other Current Liabilities03.18M3.22M12.27M2.52M
Total Current Liabilities18.67M21.65M37.15M49.07M8.87M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.79M22.17M34.43M12.22M0
Other Non-current Liabilities49.35M96K87K576K91K
Total Non-current Liabilities64.11M27.22M38.34M15.35M1.03M
Total Liabilities82.78M48.87M75.5M64.42M9.9M
Common Stock32K52K53K55K56K
Retained Earnings(367.46M)(413.88M)(391.07M)(459.64M)(451.07M)
Accumulated OCI(2K)0000
Other Stockholders Equity00000
Minority Interest00000
Total Equity88.29M75.93M106.89M46.12M59.02M
Total Debt7.34M6.65M5.54M4.3M2.9M
Net Debt(105.25M)(102.46M)(70.79M)(48.59M)(37.37M)

Spero Therapeutics, Inc.

NASDAQ:SPRO

Intrinsic Alpha fair value

Locked

Current Price

$0.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.